Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 8, 2022
Reporting Period: Single event date (February 8, 2022)
Business Context: The registrant is an emerging growth company incorporated in Nevada, with principal executive offices in Boca Raton, Florida. The company's common stock trades on The NASDAQ Stock Market LLC under the symbol "INMB".
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a specific corporate event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
No material changes to financial position or operations are reported in this document. The filing solely announces a scheduled corporate presentation.
Guidance, Outlook, and Management Commentary
Event Announcement: On February 8, 2022, the Company issued a press release (attached as Exhibit 99.1) announcing its participation in the BIO CEO & Investor Conference.
Event Details: The conference is scheduled to be held from February 14-17, 2022, at the Marriott Marquis in New York City.
Management Commentary: No specific financial guidance, risk factors, or contingencies are detailed within the body of this 8-K filing.
Investor Verification Checklist
- Verify the content of the attached press release (Exhibit 99.1) for specific details regarding the presentation at the BIO CEO & Investor Conference.
- Confirm the company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Review subsequent filings (e.g., 10-K or 10-Q) for the financial metrics absent from this report.